Loading
Mereo BioPharma Group plc Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by Denise Scots-Knight, was filed 09 Oct 2020.
Mereo BioPharma Group plc: what insiders have been doing
Mereo BioPharma Group plc belongs to the Health Care sector. Filings by its managers are published through SEC (Form 4). The past year has been quiet: not a single insider filing for Mereo BioPharma Group plc. The previous disclosure was published on 16 September 2024.
The full history, which starts in 2019, counts 22 purchases against 25 sales. For the fiscal year to 31 December 2025, the annual 10-K puts revenue at 500,000 USD and net income at -41.9 m USD.
This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Insider Decl.
97
Thresholds
n/a
Buy Volume
€289,613
22 ops. · all time
Sell Volume
€3M
25 ops. · all time
Since the insiders bought
- -1.4%Entry US$2.14 · Close at T+365 US$2.11
- -1.4%Entry US$2.14 · Close at T+365 US$2.11
- -1.4%Entry US$2.14 · Close at T+365 US$2.11
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Mereo BioPharma Group plc Buy (bullish), based on 5 analysts. Average price target: US$1.98.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 22,861 of 26,248 companies
24.7
score / 100
Value3
Quality47
FCF yld-64%
Earn yld-86%
EV/EBITDA·
ROE-68%
Gross mgn73%
Net mgn·
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$0.31
Analyst consensus
5 analystsBuy
US$0.98Target US$1.98(+546%)US$3.02
Income statement
RevenueUS$500k
Gross profitUS$367k73% margin
EBITDA-US$40.5M-8095% margin
Net income-US$41.9M-8375.6% margin
Valuation
PER (forward)-17.7x
P/Book1.7x
Beta0.14
Balance sheet & cash
Market capUS$48.9M
Total debtUS$202k
Free Cash Flow-US$31.3M
Debt / Equity4%
Profitability & ownership
ROE-67.8%
ROA-42.5%
% insiders0.7%
% institutions35.5%
Last declaration on 16 September 2024
Declarations97 total
60,046 shares@ US$4.2229.4% of flowAmerican Depositary Shares representing Ordinary SharesSEC:0000950170-24-106976:1
40,029 shares@ US$4.4711.4% of flowAmerican Depositary Shares representing Ordinary SharesSEC:0000950170-24-106968:1
16,304 shares@ US$4.224.4% of flowAmerican Depositary Shares representing Ordinary SharesSEC:0000950170-24-106968:2
84,008 shares@ US$4.2222.6% of flowAmerican Depositary Shares representing Ordinary SharesSEC:0000950170-24-106968:3
20,946 shares@ US$4.2229.4% of flowAmerican Depositary Shares representing Ordinary SharesSEC:0000950170-24-106972:1
19,158 shares@ US$4.2229.4% of flowAmerican Depositary Shares representing Ordinary SharesSEC:0000950170-24-106970:1
10,937 shares@ US$4.2229.4% of flowAmerican Depositary Shares representing Ordinary SharesSEC:0000950170-24-106974:1
9,128 shares@ US$4.472745.1% of flowAmerican Depositary Shares representing Ordinary SharesSEC:0000950170-24-106970:0
9,980 shares@ US$4.472745.1% of flowAmerican Depositary Shares representing Ordinary SharesSEC:0000950170-24-106972:0
7,769 shares@ US$4.472716.8% of flowAmerican Depositary Shares representing Ordinary SharesSEC:0000950170-24-106968:0
28,611 shares@ US$4.472745.1% of flowAmerican Depositary Shares representing Ordinary SharesSEC:0000950170-24-106976:0
5,212 shares@ US$4.472745.1% of flowAmerican Depositary Shares representing Ordinary SharesSEC:0000950170-24-106974:0
93,333 shares@ US$1.408.4% of flowAmerican Depositary Shares representing Ordinary SharesSEC:0000950170-24-106413:1
75,000 shares@ US$1.014.9% of flowAmerican Depositary Shares representing Ordinary SharesSEC:0000950170-24-106413:2
40,000 shares0American Depositary Shares representing Ordinary SharesSEC:0000950170-24-106413:0
188,060 shares0American Depositary Shares representing Ordinary SharesSEC:0000950170-24-106417:0
65,600 shares0American Depositary Shares representing Ordinary SharesSEC:0000950170-24-106426:0
60,000 shares0American Depositary Shares representing Ordinary SharesSEC:0000950170-24-106419:0
46,000 shares0American Depositary Shares representing Ordinary SharesSEC:0000950170-24-106418:0
6,492 shares@ US$1.841.9% of flowAmerican Depositary Shares representing Ordinary SharesSEC:0000950170-24-100281:1
12,418 shares@ US$2.725.5% of flowAmerican Depositary Shares representing Ordinary SharesSEC:0000950170-24-100281:2
38,953 shares@ US$1.318.3% of flowAmerican Depositary Shares representing Ordinary SharesSEC:0000950170-24-100281:3
43,485 shares@ US$0.946.6% of flowAmerican Depositary Shares representing Ordinary SharesSEC:0000950170-24-100281:4
2,071 shares@ US$3.871.3% of flowAmerican Depositary Shares representing Ordinary SharesSEC:0000950170-24-100281:5
105,244 shares@ US$4.429875.5% of flowAmerican Depositary Shares representing Ordinary SharesSEC:0000950170-24-100281:6
25 of 97 declarations
About Mereo BioPharma Group plc
Mereo BioPharma Group plc is a biopharmaceutical company focused on developing treatments for rare diseases and age-related disorders. It is listed on NASDAQ under the ticker symbol MREO.
